WPI researchers say an AI model flagged Alzheimer’s‑linked brain volume loss in hundreds of MRIs with about 93% accuracy and uncovered age‑ and sex‑specific patterns. The team is testing follow‑ups.

Gov. Mike Braun announced a $1 billion pledge to expand central Indiana’s life‑sciences and ag ecosystem, saying it could support as many as 100,000 jobs.

LVGEA and Census figures show education and health services led job gains in the Las Vegas Valley while trade, logistics and data centers also expanded hiring. Major hospital and tech investments are reshaping local demand.

Rosalind Franklin University's Helix 51 incubator is set to nearly double, adding wet‑lab space and room for more startups in North Chicago. County leaders say the buildout will deepen a growing bioscience corridor.

Lyda Hill-backed Learning Voyages will fund spring STEM trips for more than 48,000 Dallas ISD students, covering buses, admissions and curriculum-aligned programming.

Meta struck a multibillion lease with Google for TPU access, reframing compute as a metered utility and reshuffling the AI chip market. Local infrastructure choices may ripple across the Bay Area.

A Washington State University study tested 719 academic hypotheses and found ChatGPT often returned incorrect or unstable answers, prompting calls for human verification.

Brief internet outages hit the Bay Area on March 16, with Xfinity customers among those reporting dropouts and monitoring sites flagging wider spikes.

spARK Labs filled all available offices with 45 startups and has started a waitlist as it expands programming and partnerships in St. Pete’s Innovation District.

Antares, a Los Angeles microreactor startup, has raised major capital and won DOE safety clearance as it prepares to test a demonstration reactor at Idaho National Lab.

LSU and Georgia Tech launched SCEFA, a DOE-backed academy to train community leaders across the Southeast on carbon capture, starting with a January workshop and a planned citizen’s handbook.

MIT researchers traced leaky brain vessels in Rett syndrome to miR‑126‑3p; an anti‑miR drug currently in leukemia trials could offer an early path to therapy.

Stanford and other U.S. hospitals are testing CAR‑T as a one‑time treatment for progressive MS. Early data show immune effects but safety and repair of old damage remain uncertain.